Clinical Trial

DS-3201b in Participants With Lymphomas

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to current treatment This study has three parts. The Dose Escalation part is designed is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate. The Dose Expansion phase will determine how effective DS-3201b is for rare types of NH and collect additional safety data. Last, the Drug-Drug Interaction (DDI) Cohort (US Only) will evaluate the effect of DS-3201b on the pharmacokinetics (PK) of midazolam and digoxin when co-administered to patients with NHL
Protocol Amendment History 28 amendments
This ClinicalTrials.gov record has been amended 28 times since 2016-04-04; most recent amendment 2026-04-23.
Status change: Recruiting → Active, Not Recruiting 2021-12-08
Trial Details
NCT Number NCT02732275
Lead Sponsor Daiichi Sankyo Co., Ltd.
Collaborators: Daiichi Sankyo
Conditions Lymphoma, Malignant, Non-hodgkin Lymphoma
Enrollment 100 participants
Start Date 2016-03-31
Primary Completion 2022-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-28